A new class of drugs, Lu-PSMA-617, track down i prostate cancers resistant achieving good success and extending the life of patients.
This was declared by an international team of researchers including Professor Johann de Bono, Professor of Experimental Cancer Medicine at the Institute of Cancer Research, London, and Medical Oncologist Advisor at the Royal Marsden NHS Foundation Trust, and Professor Ken Herrmann, Director of the Nuclear Medicine Clinic at the University Hospital from Essen, Germany.
Read Also
- Covid-19 and back-to-school : the children are they really contagious ? Apr 30, 2020
- The main rules for raising happy and successful child Jun 10, 2020
- Made in Italy intelligent therapy against rare lung cancer and other solid neoplasms Sep 15, 2021
- Ten symptoms that indicate high cholesterol Aug 11, 2020
- Covid, Di Domenico (Gsk): “Against viruses and variants monoclonal antibodies are the extra weapon” Jul 13, 2021
- A BBC journalist died of complications from the AstraZeneca vaccine, research shows Aug 26, 2021
- Covid-19 : the story of a discovery on the hydroxychloroquine ! Jul 13, 2020